188 related articles for article (PubMed ID: 31692012)
1. The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
Lu ZN; Luo Q; Zhao LN; Shi Y; Wang N; Wang L; Han ZG
Hepatology; 2020 Mar; 71(3):929-942. PubMed ID: 31692012
[TBL] [Abstract][Full Text] [Related]
2. The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.
Sborchia M; De Prez EG; Antoine MH; Bienfait L; Indra R; Valbuena G; Phillips DH; Nortier JL; Stiborová M; Keun HC; Arlt VM
Arch Toxicol; 2019 Nov; 93(11):3345-3366. PubMed ID: 31602497
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats.
Liu YZ; Lu HL; Qi XM; Xing GZ; Wang X; Yu P; Liu L; Yang FF; Ding XL; Zhang ZA; Deng ZP; Gong LK; Ren J
Acta Pharmacol Sin; 2021 Dec; 42(12):2094-2105. PubMed ID: 33686245
[TBL] [Abstract][Full Text] [Related]
4. Aristolochic acids exposure was not the main cause of liver tumorigenesis in adulthood.
Chen S; Dong Y; Qi X; Cao Q; Luo T; Bai Z; He H; Fan Z; Xu L; Xing G; Wang C; Jin Z; Li Z; Chen L; Zhong Y; Wang J; Ge J; Xiao X; Bian X; Wen W; Ren J; Wang H
Acta Pharm Sin B; 2022 May; 12(5):2252-2267. PubMed ID: 35646530
[TBL] [Abstract][Full Text] [Related]
5. Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats.
Bárta F; Dedíková A; Bebová M; Dušková Š; Mráz J; Schmeiser HH; Arlt VM; Hodek P; Stiborová M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638820
[TBL] [Abstract][Full Text] [Related]
6. Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid.
Nault JC; Letouzé E
Semin Liver Dis; 2019 Jul; 39(3):334-340. PubMed ID: 31041788
[TBL] [Abstract][Full Text] [Related]
7. Study on the potential nephrotoxicity and mutagenicity of aristolochic acid IVa and its mechanism.
Xian Z; Tian J; Zhang Y; Meng J; Zhao Y; Li C; Yi Y; Han J; Liu S; Wang L; Pan C; Wang D; Wang F; Liang A
Biomed Pharmacother; 2021 Oct; 142():112081. PubMed ID: 34463271
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models.
Bastek H; Zubel T; Stemmer K; Mangerich A; Beneke S; Dietrich DR
Toxicology; 2019 May; 420():29-38. PubMed ID: 30940547
[TBL] [Abstract][Full Text] [Related]
9. Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice.
Arlt VM; Zuo J; Trenz K; Roufosse CA; Lord GM; Nortier JL; Schmeiser HH; Hollstein M; Phillips DH
Int J Cancer; 2011 Jan; 128(1):21-32. PubMed ID: 20232387
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells.
Bellamri M; Brandt K; Brown CV; Wu MT; Turesky RJ
Arch Toxicol; 2021 Jun; 95(6):2189-2199. PubMed ID: 33938965
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.
Simões ML; Hockley SL; Schwerdtle T; Gamboa da Costa G; Schmeiser HH; Phillips DH; Arlt VM
Toxicol Appl Pharmacol; 2008 Oct; 232(1):86-98. PubMed ID: 18639569
[TBL] [Abstract][Full Text] [Related]
12. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR.
Arlt VM; Schmeiser HH; Pfeifer GP
Carcinogenesis; 2001 Jan; 22(1):133-40. PubMed ID: 11159751
[TBL] [Abstract][Full Text] [Related]
13. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences.
Feldmeyer N; Schmeiser HH; Muehlbauer KR; Belharazem D; Knyazev Y; Nedelko T; Hollstein M
Mutat Res; 2006 Sep; 608(2):163-8. PubMed ID: 16835015
[TBL] [Abstract][Full Text] [Related]
14. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy.
Bieler CA; Stiborova M; Wiessler M; Cosyns JP; van Ypersele de Strihou C; Schmeiser HH
Carcinogenesis; 1997 May; 18(5):1063-7. PubMed ID: 9163697
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney.
Xing G; Qi X; Chen M; Wu Y; Yao J; Gong L; Nohmi T; Luan Y; Ren J
Mutat Res; 2012 Mar; 743(1-2):52-8. PubMed ID: 22245565
[TBL] [Abstract][Full Text] [Related]
16. The Impact of p53 on Aristolochic Acid I-Induced Gene Expression In Vivo.
Sborchia M; Keun HC; Phillips DH; Arlt VM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817608
[TBL] [Abstract][Full Text] [Related]
17. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
18. ACB-PCR measurement of H-ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues.
Wang Y; Arlt VM; Roufosse CA; McKim KL; Myers MB; Phillips DH; Parsons BL
Environ Mol Mutagen; 2012 Aug; 53(7):495-504. PubMed ID: 22729866
[TBL] [Abstract][Full Text] [Related]
19. Defining in vivo dose-response curves for kidney DNA adduct formation of aristolochic acid I in rat, mouse and human by an in vitro and physiologically based kinetic modeling approach.
Abdullah R; Wesseling S; Spenkelink B; Louisse J; Punt A; Rietjens IMCM
J Appl Toxicol; 2020 Dec; 40(12):1647-1660. PubMed ID: 33034907
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis.
Aydin S; Ambroise J; Cosyns JP; Gala JL
Mutat Res Genet Toxicol Environ Mutagen; 2017 Jun; 818():17-26. PubMed ID: 28477877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
